BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 25, 2019
View Archived Issues
Study shows TINCR lncRNA overexpression in epithelial ovarian cancer and role in tumor progression
Read More
Upadacitinib demonstrates promising safety and efficacy in phase II/III SELECT-AXIS 1 study
Read More
Hepatic YBX1 as a novel therapeutic target for obesity-related liver disorders
Read More
Klotho shows potential as therapeutic target in podocyte injury of diabetic nephropathy
Read More
Phase I data presented for TPI-287 in Alzheimer's disease and 4-repeat tauopathies
Read More
CLCA1-TMEM16A-chloride current pathway mediates renal injury in aging and diabetes
Read More
Discovery of targetable dopamine receptor controlling childhood-onset asthma
Read More
NASH progression tied to redox state
Read More
Leptin affects T-cell metabolism
Read More
New pan alphav antagonist with excellent oral PK properties and bioavailability for IPF treatment
Read More
Amgen discovers KRAS G12C inhibitors
Read More
New RIP-1 inhibitors identified at Rigel Pharmaceuticals
Read More
Shanghai Longwood Biopharmaceuticals patents HBV caspid assembly inhibitors
Read More
Medshine Discovery describes new HER2 inhibitors
Read More
Johnson & Johnson identifies new anti-HBV compounds
Read More
Neuraly studies NLY-01 in phase II for type 2 diabetes
Read More
Clinical data presented for AT-001 in patients with T2D-derived diabetic cardiomyopathy
Read More
Oyster Point Pharma reports topline phase I results with OC-01 nasal spray for dry eye
Read More
EI-1071 to enter phase I testing next year
Read More
Dynamin-2 is upregulated in pulmonary arterial hypertension
Read More
AKCEA-TTR-LRx begins phase III trial for polyneuropathy caused by hATTR amyloidosis
Read More
New phase III trial evaluates oral formulation of edaravone for ALS
Read More
Soliris approved in Japan for neuromyelitis optica spectrum disorder
Read More
